KEY FINDINGS
The Europe neurovascular devices / interventional neurology market growth is anticipated to progress at a CAGR of 4.87% during the forecast period, 2021-2028. The surging prevalence of neurovascular diseases boosts the market growth. For instance, there will be a 34% increase in stroke incidences between 2015 and 2035, as per the Stroke Alliance for Europe.
MARKET INSIGHTS
Poland, Italy, the United Kingdom, Germany, Belgium, Russia, France, and Rest of Europe, are evaluated for the Europe neurovascular devices / interventional neurology market growth analysis. Germany has a world-class healthcare system that offers cost-effective treatment. As per The Burden of Stroke in Europe report by the King’s College, London, the stroke incidence rate is 51.7 per 100,000 in the country. Also, Germany has a considerable mortality rate due to stroke, with almost 75,861 deaths annually. With an expectant increase in such incidences, the demand for neurovascular diseases is projected to increase during the forecast period.
In Italy, the healthcare system is witnessing growth with developments in neurology. As per the XLVII Congress of the Italian Society of Neurology’s report, more than 1 million have dementia. Every year 120,000 people are affected by stroke, and another 930,000 are affected by the disability caused by stroke. Also, Italy has a growing senior population, contributing to increasing cases of neurological disorders like Parkinson’s disease and multiple sclerosis. In Spain, stroke is the third leading cause of death after Alzheimer’s disease and ischemic heart stroke. Also, the government has increased its investment in healthcare systems. Such factors facilitate market growth in these countries.
COMPETITIVE INSIGHTS
Some of the eminent firms in the market are B Braun Melsungen AG, Phenox GmbH, Rapid Medical, Microport Scientific Corporation, Kaneka Corporation, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCIDENCE OF NEUROVASCULAR CONDITIONS
3.1.2. DEMAND FOR MINIMALLY INVASIVE PROCEDURES
3.1.3. SIGNIFICANCE OF NEUROLOGICAL DISEASES IN GERIATRIC POPULATION
3.1.4. PREVALENCE OF UNDERLYING DISEASE CONDITIONS
3.2. KEY RESTRAINTS
3.2.1. EXORBITANT COST OF NEUROVASCULAR DEVICES
3.2.2. LACK OF ADEQUATE NUMBER OF TRAINED NEUROSURGEONS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY PRODUCT
5.1. EMBOLIZATION DEVICES
5.2. ACCESSORY DEVICES
5.3. REVASCULARIZATION DEVICES
5.4. THROMBECTOMY DEVICES
5.5. EMBOLIC PROTECTION DEVICES
6. MARKET BY APPLICATION
6.1. ANEURYSM
6.2. ISCHEMIC STROKE
6.3. STENOSIS
6.4. ARTERIOVENOUS MALFORMATION (AVM)
6.5. OTHER APPLICATIONS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. KEY GROWTH ENABLERS
7.1.3. KEY CHALLENGES
7.1.4. KEY PLAYERS
7.1.5. COUNTRY ANALYSIS
7.1.5.1. GERMANY
7.1.5.2. UNITED KINGDOM
7.1.5.3. FRANCE
7.1.5.4. ITALY
7.1.5.5. RUSSIA
7.1.5.6. POLAND
7.1.5.7. BELGIUM
7.1.5.8. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. ACANDIS GMBH
8.2.2. ASAHI INTECC
8.2.3. B BRAUN MELSUNGEN AG
8.2.4. INTEGER HOLDINGS CORPORATION
8.2.5. JOHNSON & JOHNSON (CERENOVUS)
8.2.6. KANEKA CORPORATION
8.2.7. MEDTRONIC INC
8.2.8. MEMRY CORPORATION
8.2.9. MICROPORT SCIENTIFIC CORPORATION
8.2.10. PENUMBRA INC
8.2.11. PHENOX GMBH
8.2.12. RAPID MEDICAL
8.2.13. SENSOME
8.2.14. STRYKER CORPORATION
8.2.15. TERUMO MEDICAL CORPORATION (MICROVENTION INC)
1. ACANDIS GMBH
2. ASAHI INTECC
3. BALT
4. B BRAUN MELSUNGEN AG
5. INTEGER HOLDINGS CORPORATION
6. JOHNSON & JOHNSON (CERENOVUS)
7. KANEKA CORPORATION
8. MEDTRONIC INC
9. MEMRY CORPORATION
10. MICROPORT SCIENTIFIC CORPORATION
11. PENUMBRA INC
12. PHENOX GMBH
13. RAPID MEDICAL
14. SENSOME
15. STRYKER CORPORATION
16. TERUMO MEDICAL CORPORATION (MICROVENTION INC)